Although systemic chemotherapy and emerging KRAS-targeting therapies in NSCLC, PDAC and CRC as well as immunotherapy in NSCLC offer some benefit, they often fail to achieve durable responses, underscoring the need for alternative therapeutic modalities effective as a single agent or combination partner10–14. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.